Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Combined (SoliQ) molecular profiling using whole exome sequencing in advanced HNSCC at baseline: Lessons learned for prognostication and treatment planning.

Vidya Veldore, Vanita Noronha, Vijay Maruti Patil et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18025

e18025 Background: HNSCC imparts rising incidence and mortality rate worldwide, due to lack of information regarding spatial and temporal heterogeneity of...

Retrospective single-institution application of a deep learning–based radiomic score in metastatic NSCLC: Potential impact on first-line treatment decisions and outcomes.

Nicholas Campbell Love, Karishma Sewaramani, Ross McCall et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20608

e20608 Background: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are standard of care for metastatic non-small cell lung cancer (mNSCL...

National trends in disability-adjusted life years (DALYs) of pancreatic cancer among individuals aged 70 and older across 204 countries (1990-2021): A global burden of disease study.

Sardar Muhammad Imran Khan, Abdul Qadeer, Muneeb Khawar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22572

e22572 Background: Pancreatic cancer is a highly lethal malignancy that disproportionately impacts older populations, contributing significantly to global...

Omission of elective neck irradiation in pT3-T4 oral squamous cell carcinoma with a pN0 neck: Impact on regional control and overall survival.

Mathilde Mirallie, Anoushka Modesto, Marie Christelle Pajiep Chapda et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18091

e18091 Background: Postoperative radiotherapy is commonly indicated for the treatment of locally advanced oral squamous cell carcinoma (OSCC). However, fo...

Outcomes of patients with technically resectable stage III non-small cell lung cancer treated with concurrent chemoradiation followed by durvalumab consolidation.

Spencer Erickson, Keith Cordner, Tawakalito Alabi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20013

e20013 Background: Patients with early stage non-small cell lung cancer (NSCLC) benefit from surgical resection when feasible. The PACIFIC trial showed th...

Sepsis-related outcomes and the healthcare burden in esophageal cancer patients with atrial fibrillation: A national database study.

Adamsegd Isac Gebremedhen, Abdu Mohammed, Mamdouh Souleymane et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16002

e16002 Background: Among solid tumors, esophageal cancer (EC) is notably associated with atrial fibrillation (AF). The development of AF in EC is influenc...

A 25-year perspective on tongue cancer-related mortality: Nationwide trends and disparities in the United States.

Masab Ali, Humza Saeed, Muhammad Musaddique Khan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22543

e22543 Background: Tongue cancer represents a significant proportion of oropharyngeal cancers. Despite advances in treatment, disparities in mortality per...

Should radiotherapy be considered for the initial treatment of ovarian cancer brain metastases? Findings from a 12-year multicenter retrospective study.

Yingying Wang, Tao Zhu, Chunyan Lan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17541

e17541 Background: Ovarian cancer brain metastases (OCBM) are rare and have poor prognosis, with limited clinical guidelines. This study aims to identify...

Incidence of brain metastases in lung cancer patients with high PD-L1 expression (>50%) compared to low PD-L1 expression (<1%).

Akash Patel, Ujwal Aluru, Alane Rogers et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20533

e20533 Background: Programmed cell death protein 1 (PD1) is a cell membrane receptor that primarily works to activate T cells and to inhibit the apoptosis...

Combined hepatocellular cholangiocarcinoma: A population-based retrospective study.

Takashi Kokudo, Yasuhide Yamada, Mai Nakamura et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16291

e16291 Background: In 2011, the Ministry of Health, Labor and Welfare started providing data from the National Database of Health Insurance Claims and Spe...

Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study.

Jia Zhong, Jin Zhou, Qian Chu et al. Jun 01, 2025 pp. 8520-8520 10.1200/jco.2025.43.16_suppl.8520

8520 Background: KRAS G12C mutation is a poor prognostic factor for Non-Small Cell Lung Cancer (NSCLC). Sosimerasib is a novel potent and highly selective...

Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment.

Vittorio Studiale, Kristiyana Kaneva, Roberto Moretto et al. Jun 01, 2025 pp. 3544-3544 10.1200/jco.2025.43.16_suppl.3544

3544 Background: Liver-limited disease (LLD) occurs in 20-30% of metastatic colorectal cancer (mCRC) patients. Although 20-30% of patients who undergo res...

Unveiling the power of PARP inhibitors: A meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy.

Wanfang Zhang, Ni Zhang, Shaojie Li et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17573

e17573 Background: The treatment of ovarian cancer with poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPi) is undergoing continuous...

Lymphatic mapping to the inguinal region in patients with lower extremity melanoma undergoing radical inguinal lymph node dissection: A retrospective cohort study.

Jiayong Liu, Zhichao Tan, Zhengfu Fan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21567

e21567 Background: Radical inguinal lymph node dissection (rILND) is the standard procedure for malignant melanoma (MM) patients with clinically positive...

Impact of palliative chemotherapy in hospitalized patients with advanced solid tumors.

Sydney Roussel, Leila Mohassel, Kendra Jones et al. Jun 01, 2025 pp. 11150-11150 10.1200/jco.2025.43.16_suppl.11150

11150 Background: The role of palliative chemotherapy (PC) in patients with advanced solid tumors and poor performance status (PS) remains uncertain since...

Final results of a phase 2 study of HDACi chidamide and PD-1 inhibitor for advanced urothelial carcinoma after platinum therapy.

Zhuowei Liu, Lijuan Jiang, Li Tian et al. Jun 01, 2025 pp. 4563-4563 10.1200/jco.2025.43.16_suppl.4563

4563 Background: Epigenetic dysregulation is commonly correlated with the pathogenesis and development in urothelial carci...

Treatment patterns and out-of-pocket cost after CAR-T cell therapy in commercially insured patients with hematologic malignancies: A real-world US study.

Mohammed Zuber, Shaimaa Elshafie, Shifa Taj et al. Jun 01, 2025 pp. 11045-11045 10.1200/jco.2025.43.16_suppl.11045

11045 Background: Chimeric Antigen Receptor T (CAR-T) cell therapy has improved outcomes in hematologic malignancies since its FDA approval in 2017. Howev...

Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.

Salomon Manier, Enrique M. Ocio, Carmen Martínez-Chamorro et al. Jun 01, 2025 pp. 7513-7513 10.1200/jco.2025.43.16_suppl.7513

7513 Background: LINVO, a T-cell redirecting BCMA×CD3 bispecific antibody, has demonstrated high efficacy and generally manageable safety in triple-class...

Perfume trial: Phase II trial of binimetinib in patients with <i>BRAF</i> fusion-positive low-grade glioma or pancreatic cancer.

Tomoyuki Satake, Makoto Ohno, Chiharu Mizoguchi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3188

TPS3188 Background: BRAF fusion was reported to be a rare mutation found in 0.3% of all solid tumors, but a high percentage of BRAF fusion has...

A systemic trend analysis of young onset esophageal cancer in American population, 2012-2021.

Anh Trinh Doan, Michelle Min, Lucas Wong et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16098

e16098 Background: Esophageal adenocarcinoma (EAC) is a rapidly growing cancer in the United States. Although often associated with older populations, the...

A prospective randomized controlled study about oral nutrition supplement in local advanced nasopharyngeal carcinoma patients: An update of long-term survival.

Shuang Huang, Caineng Cao, Mengyun Qiang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18018

e18018 Background : Radiotherapy will aggravate malnutrition of nasopharyngeal carcinoma (NPC) patients and influence the prognosis. However,...

The addition of abemaciclib to endocrine therapy versus endocrine therapy alone in HR+/HER2− advanced breast cancer: A meta-analysis.

Mohammed S. Beshr, Rana H. Shembesh, Mohamed E. Ali et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13167

e13167 Background: Abemaciclib represents a significant therapeutic advancement in the treatment of advanced metastatic breast cancer. As a selective prot...

Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated <i>KRAS</i> G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).

John H. Strickler, Yasutoshi Kuboki, David S. Hong et al. Jun 01, 2025 pp. 3506-3506 10.1200/jco.2025.43.16_suppl.3506

3506 Background: In the phase 3 CodeBreaK 300 trial (NCT05198934), the combination of sotorasib (KRAS...

Novel dynamic circulating biomarkers for predicting therapeutic efficacy of PRaG regimen in advanced refractory solid tumors.

Yuehong Kong, Shicheng Li, Rongzheng Chen et al. Jun 01, 2025 pp. 2548-2548 10.1200/jco.2025.43.16_suppl.2548

2548 Background: Common biomarkers for predicting the efficacy of immune checkpoint inhibitors (ICIs), such as programmed death-ligand 1 (PD-L1) expressio...

Cardiometabolic health in men with prostate cancer under active surveillance following a home-based exercise program—A secondary analysis.

Alice Lee, Darpan Patel Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22617

e22617 Background: Prostate cancer (PCa) is the most common cancer affecting men in the US, with cardiovascular disease and neurologic decline being commo...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page